News | August 22, 2014

Proton Therapy Offers Safe, Long-term Treatment for Hodgkin Lymphoma

Findings of the new American study correspond to the results of Proton Therapy Center Czech

Proton Therapy Safe Long-term Treatment Hodgkin Lymphoma Study Florida

August 22, 14 — The data by the University of Florida Proton Therapy Institute (UFPTI) shows a three-year relapse-free rate of 93 percent and a three-year event-free rate of 87 percent. "This study reinforces proton therapy as a safe alternative to the more conventional forms of radiation," said lead researcher Bradford S. Hoppe, M.D., radiation oncologist at the UF Proton Therapy Institute and assistant professor in the University of Florida College of Medicine department of radiation oncology.

The study continues to add to the mounting evidence supporting the use of proton radiation therapy for positive long-term treatment outcomes and quality of life of oncology patients. For instance, none of the patients developed grade three or higher toxicity during follow-up. The UFPTI specialists agreed that the use of proton therapy following chemotherapy in patients with Hodgkin lymphoma has a success rate similar to the conventional treatments with a reduction of radiation outside of the target area, or "involved-node," potentially reducing the risk of late effects caused by radiation.

The study tracked 15 patients between September 2009 and June 2013 with newly diagnosed Hodgkin lymphoma as they received involved-node proton therapy (INPT), which specifically targets initially involved lymph node(s) containing the Hodgkin lymphoma, after completing chemotherapy. Further, the study evaluated the radiation dose in the surrounding healthy tissue as a result of proton therapy compared with conventional treatments, called intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3DCRT).

Despite some success in treating patients with Hodgkin lymphoma, many patients suffer from late effects of radiation therapy and chemotherapy treatment, including the possible onset of breast cancer or heart disease. "Proton therapy, as opposed to similar conventional photon therapy, reduced the risk of long-term side effects by reducing or eliminating radiation doses to healthy tissue without compromising the cure rate," said lead researcher Bradford S. Hoppe.

The clinical results of Proton Therapy Center Czech, based on treatment of dozens of patients with Hodgkin lymphoma, correspond with the findings of the American study. “Proton therapy was approved for its clinical use in 1992 and has been used for treatment of selected stages of Hodgkin and non-Hodgkin lymphoma based on NCCN guidelines (National Comprehensive Cancer Network) since 2013,” adds doctor Jiri Kubes, Ph.D., the head of proton therapy at PTC Czech.

Comparison of treatment plans is the right and standard process used in radiation oncology, which enables us to foresee the possible risk of side effects and decide for the most appropriate treatment for each patient. This type of data is also important for examining the effectiveness of radiotherapy in general. Based on the international statistics, radiotherapy should be used for more than 50 percent of oncology patients during their treatment,” said Kubeš.

For more information: www.medicalnewstoday.com/releases/278648.php, www.lymphoma.eu.com

Related Content

Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
ProTom International received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radiance 330 proton therapy system
News | Proton Therapy | October 07, 2019
ProTom International received 510(k) clearance from the U.S.
Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System
News | Proton Therapy | September 20, 2019
Varian announced its ProBeam 360° proton therapy system is now available in a multi-room configuration. The ProBeam 360...
IBA Gathers Experts on Flash Irradiation During ASTRO
News | Proton Therapy | September 17, 2019
IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019...
Civco Highlights Universal Couchtop ProForm at ASTRO 2019
News | Patient Positioning Radiation Therapy | August 30, 2019
Civco will display its Universal Couchtop ProForm Head & Neck Solution at the 2019 American Society for Radiation...
Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

News | Patient Positioning Radiation Therapy | August 15, 2019
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton...
MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

News | Proton Therapy | August 08, 2019
The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a...
Qfix kVue One Proton Couch Top Validated by Mevion Medical Systems
News | Patient Positioning Radiation Therapy | August 07, 2019
Qfix and Mevion Medical Systems announced that a special version of the kVue One Proton couch top is now both validated...
IBA Signs Contract to Install Proton Therapy Center in Kansas
News | Proton Therapy | August 06, 2019
IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution...